ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Disparities and Determinants of Cancer Treatment in Elderly Americans Living With Human Immunodeficiency Virus/AIDS.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Risk of prostate cancer in men with HIV/AIDS: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2021Pooled it
- Health-related quality of life among adult cancer patients with and without HIV: Analysis of SEER-MHOS data (2007-2017).Journal of geriatric oncology · 2026Article
- Article
- Inequities by race and ethnicity in cancer treatment receipt among people living with HIV and cancer in the U.S. (2004-2020).BMC cancer · 2025Article
- Inequities in palliative care delivery to patients with HIV and stage IV cancers in the United States (2004-2020).JNCI cancer spectrum · 2025Article
- Patterns and predictors of opioid dispensing among older cancer patients from 2008 to 2015.Cancer medicine · 2024Article
- An update on drug-drug interactions in older adults living with human immunodeficiency virus (HIV).Expert review of clinical pharmacology · 2024Review
- A clinical overview of people living with HIV and genitourinary cancer care.Nature reviews. Urology · 2024Review
- Cancer Treatment Disparities in People With HIV in the United States, 2001-2019.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Incidence of Colon Cancer Among Medicaid Beneficiaries With or Without Human Immunodeficiency Virus Under Comparable Colorectal Cancer Screening Patterns.Open forum infectious diseases · 2024Article
- State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI.International journal of cancer · 2024Review
- Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV.JAMA network open · 2023Article
- The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer.The oncologist · 2023Article
- Selection and Prejudice: Addressing Clinical Trial Disparities With a Review of Current Shortcomings and Future Directions.Seminars in radiation oncology · 2023Review
- Cancer treatment delays among cancer patients living with HIV during the COVID-19 pandemic in the United States.Cancer medicine · 2023Article
- Palliative Care Use Among People Living With HIV and Cancer: An Analysis of the National Cancer Database (2004-2018).JCO oncology practice · 2022Article
- Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer.Journal for immunotherapy of cancer · 2022Article
- Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study.The oncologist · 2022Article
- Epidemiology of Cervical Adenocarcinoma and Squamous Cell Carcinoma Among Women Living With Human Immunodeficiency Virus Compared With the General Population in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- HIV, cancer, and coping: The cumulative burden of a cancer diagnosis among people living with HIV.Journal of psychosocial oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Background: Previous studies suggest that human immunodeficiency virus (HIV)-infected cancer patients are less likely to receive cancer treatment. The extent to which this disparity affects the growing population of elderly individuals is unknown and factors that mediate these treatment differences have not been explored. Methods: We studied 930359 Americans aged 66-99 years who were diagnosed with 10 common cancers. Surveillance, Epidemiology, and End Results-Medicare claims from 1991 to 2011 were used to determine HIV status and receipt of cancer treatment in 6 months following diagnosis. Mediation analysis was conducted to estimate the direct effect of HIV, and indirect effect through cancer stage at diagnosis and comorbidities, on cancer treatment. Results: HIV-infected individuals (n = 687) were less likely to receive cancer treatment (70% vs 75% HIV uninfected; P < .01). This difference was larger in individuals aged 66-70 years, among whom only 65% were treated (vs 81% in HIV uninfected; P < .01), and time from cancer diagnosis to treatment was longer (median, 42.5 vs 36 days in HIV uninfected; P < .01). Accounting for potential confounders, HIV-infected individuals aged 66-70 years remained 20% less likely to receive cancer treatment (hazard ratio, 0.81 [95% confidence interval, .71-.92]). Seventy-five percent of this total effect was due to HIV itself, with a nonsignificant 24% mediated by cancer stage and comorbidities. Conclusions: Lowest cancer treatment rates were seen in the younger subset of HIV-infected individuals, who would likely benefit most from treatment in terms of life expectancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.